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      INTRODUCTION 
The exact in vitro inhibitory mechanism of 
Chloroquine on corona virus has already been 
published in a study report.1 Based on relevant 
studies on chloroquine and hydroxychloroquine in 
the treatment of COVID-19, the inclusion of these 
drugs was recommended for treating this 
pandemic. Both chloroquine and its analogue 
hydroxychloroquine fall into the 4-
aminoquinoline class of antimalarials and have 
some application in the treatment of rheumatoid 
arthritis, systemic lupus erythematosus, and other 
connective tissue diseases in addition to malaria. 
Its adverse effects include gastrointestinal 
reactions, skin and hair damage, neuromuscular 
abnormalities and eye lesions.2  
 
Coronavirus is a kind of enveloped positive-sense 
RNA virus named after its coronal appearance 
under electron microscope. SARS-CoV-2, severe 
acute respiratory syndrome coronavirus and 
Middle East respiratory syndrome coronavirus 
belong to β genus coronavirus.3 Early studies of 
SARS-CoV found that chloroquine could inhibit 
coronavirus replication by reducing terminal 
glycosylation of ACE2 receptors on the cell surface 
and interfering with viral binding to angiotensin 
converting enzyme 2 receptors.4 Because the 
SARS-CoV-2 gene sequence has high homology 
with SARS-CoV5, especially its similarity to the 
spike glycoprotein bound by the cell surface ACE2 
receptor6, the researchers used chloroquine to 






to the mechanism and confirmed that it had a 
clear inhibitory effect on SARS-CoV-2 in vitro.1  
 
In ophthalmic clinical work, the retinal toxicity of 
CQ and HCQ is a common cause of drug-induced 
retinopathy, and its exact mechanism still remains 
unclear. The incidence of retinal maculopathy 
induced by CQ has been reported to be about 10% 
- 25%7, and the incidence of retinopathy after 
more than 5 years of HCQ use is about 7.5%.8  
 
Although HCQ is safer than CQ, both drugs can 
cause irreversible retinal damage, and their retinal 
toxicity mainly damages photoreceptor cells, 
mainly in the form of degeneration of the outer 
nuclear layer of the retina in the early stage, and 
patients are usually asymptomatic, but show 
abnormalities in fundus examination or diagnostic 
tests9 and damage to the retinal pigment 
epithelium occurs in the late stage.10 If damage is 
found before RPE damage occurs and the drug is 
discontinued in a timely manner, central visual 
acuity can be preserved11, and if found late, it can 
lead to irreversible visual loss, and there is no 
effective treatment.12 Therefore, in the treatment 
of COVID-19 patients with CQ and HCQ, it is 
necessary to guard against the risk of drug-
induced retinopathy, and it is recommended to 
perform relevant ophthalmic screening in a proper 
way to maintain the incidence of drug toxicity at a 
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 The use of chloroquine and hydroxychloroquine in the tough time of COVID-19 has gained much attention. The production and use of these 
drugs has drastically increased in the past few months. However, it is important to know that retinal toxicity is a very rare side effect of these 
therapies that can lead to permanent vision loss. The mechanism is however unclear, but this toxicity might depend on the tolerance of the 
subjects exposed. It is important to choose the appropriate dosage which should be customized as per the patient’s condition, age, body weight 
and comorbidities. Also, to avoid the occurrence of retinopathy, eye examination and ophthalmic screening for the patients being administered 
these drugs should be done. This review discusses the risk determinants, the clinical presentations and screening techniques of retinal toxicity. 
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The mechanism by which CQ and HCQ produce 
retinal toxicity is still unclear, and current studies 
mostly focus on their effects on retinal cell 
metabolism and function. Evaluation of rhesus 
monkey eye tissues chronically administered CQ 
showed that CQ was widely bound in pigmented 
ocular tissues (RPE, iris, choroid, and ciliary body) 
and eventually accumulated in the retina, which 
may represent one of the causes for retinal 
toxicity.13 The study of RPE cells treated with CQ 
and HCQ found that both CQ and HCQ inhibited 
the uptake of organic anion-transporting 
polypeptide 1A2 and inhibited the cyclic 
absorption of all-trans retinol in RPE cells, 
suggesting that they might have an effect on the 
visual cycle.14  
 
It has been suggested in previous studies that 
melanin in RPE may concentrate HCQ and 
enhance its toxicity, but melanin also has a role in 
helping RPE cells to remove intrinsic toxic 
substances.15,16 An in vitro study has also found 
that CQ and HCQ can increase the permeability of 
RPE cells and may also exert some effects on the 
function of RPE cells.17 A recent study found that 
the toxicity of CQ on RPE cells might be related to 
the downregulation of p150 glued protein 
expression, which in turn inhibited the 
proliferation and microtubule nucleation of RPE 
cells.18  
 
Other scholars have proposed that HCQ-induced 
retinal degeneration occurs in the retinal 
photoreceptor cell layer; since HCQ can affect the 
pH and function of lysosomes, it may affect the 
autophagic function of RPE, which in turn affects 
the stability of photoreceptor cell membranes and 
ultimately produces retinal toxicity.10-19 In a study 
of optic ganglion cells exposed to CQ, it was found 
that the retinal toxicity of CQ might affect visual 
conduction by changing the dynamics of acid 
sensing ion channel 1a in RGCs.20 These studies, 
however, focus on the acute effects of drugs on 
retinal cells and do not fully reveal the exact 
mechanism of chronic retinal toxicity in clinical 
patients. 
 
Dosage is the most important risk factor for retinal 
toxicity caused by CQ and HCQ. The safe dose of 
CQ and HCQ recommended by the American 
Academy of Ophthalmology in 2016 
Recommendations on Screening for Chloroquine 
(CQ) and Hydroxychloroquine (HCQ) 
Retinopathy is 2.3 mg/kg and 5 mg/kg daily, 
respectively, and it is pointed out that attention 
should still be paid to adjusting the dose for 
patients with short stature and low body mass.21 
 
A previous study has found that the application of 
a dose > 5.0 mg/kg significantly increases the risk 
of retinopathy, especially the use of extremely 
high doses.8 Recent studies have revealed that the 
incidence of retinopathy within 1 to 2 years can be 
25% to 40% in patients treated with HCQ at 800 - 
1000 mg (approximately 20 mg/kg) daily.22-23 In 
contrast, the incidence of retinopathy within 5 
years was less than 1% in case of HCQ treatment at 
low doses of 4.0 - 5.0 mg/kg.8 Therefore, the use of 
CQ or HCQ in the treatment of COVID-19 should 
be controlled as far as possible within the safe 
dose range. At present, in the clinical studies 
registered in China for the treatment of COVID-19, 
the recommended dosage of chloroquine 
phosphate is 0.5 ~ 1g oral daily.24 The duration of 
medication is inseparable from the dose of 
medication and is also a risk factor for retinal 
toxicity caused by CQ and HCQ. Patients with 
retinopathy caused by CQ and HCQ mostly have a 
long history of medication, but acute toxic 
retinopathy caused by high-dose chloroquine 
requires increased vigilance. Because CQ and 
HCQ are slowly excreted from the human body 
and carry some risks after long-term use even at 
the recommended dose, a previous study has 
pointed out that the cumulative dose of the drug 
may be associated with the occurrence of 
retinopathy.25 Therefore, it is recommended that, 
for patients who use CQ and HCQ for a long time, 
their the previous medication history after starting 
treatment with CQ or HCQ should be carefully 
reviewed and attention should be paid to the 
presence or absence of visual impairment during 
their medication, and the patients should 
cooperate with timely screening. 
 
CQ and HCQ are mainly eliminated via the 
kidneys, and a study has found that patients with 
renal diseases are at higher risk of drug toxicity.26 
The liver is also involved in the metabolism of CQ 
and HCQ, but there is no clear evidence of an 
association between liver disease and retinal 
toxicity. Since critically ill patients with COVID-19 
often present with systemic multiple organ 
failure27, and unpredictable levels in blood may 
occur with impaired liver and kidney function, so 
the dose used and the frequency of ophthalmic 
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screening are recommended to be adjusted 
moderately according to the patient's plasma 
concentration. The patients with retinal or 
macular disease may be at a higher risk for 
retinopathy, and it is clinically recommended that 
the drugs with retinal toxicity should not be used 
if patients have the underlying diseases of retinal 
dystrophy or severe degeneration. At the same 
time, patients with retinal or macular diseases 
may lead to abnormal testing results, which may 
interfere with ophthalmic screening during 
medication. Therefore, caution should be 
exercised for the use of CQ and HCQ in patients 
with underlying eye diseases.21  
 
It is recommended to perform proper baseline 
examination to rule out retinal or macular diseases 
and learn the basic conditions of the patient's 
retina. Clinically, it is believed that elderly patients 
may be at risk of retinopathy due to their weak 
resistance to drug toxicity and slow rate of drug 
metabolism. However, recent demographic studies 
have found no definitive link between age and the 
risk of ocular toxicity with drugs.8 It has been 
shown that some patients with ABCA4 gene 
abnormalities have genetic predisposition to HCQ 
retinal toxicity28 A new study has suggested that 
some non-pathogenic polymorphic ABCA4, such 
as small alleles of common genetic variants in 
ABCA4, may instead have a protective effect.29 
Genetic polymorphisms in cytochrome P450 may 
also affect plasma concentrations as well as the 
ocular toxicity of drugs.30  
 
Early patients with retinopathy caused by CQ and 
HCQ usually present with normal vision or even 
without any visual symptoms, and only a few 
patients may present with paracentral scotomas 
and fine punctate pigment spots in the macular 
area during reading. If exposure to drugs is 
continued, the dysfunctional area expands, RPE is 
involved, characteristic bullseye maculopathy may 
occur in the fundus, visual acuity decreases, and 
late lesions invade the fovea, resulting in loss of 
visual acuity; in addition, macular cystic edema 
may also occur, with extensive RPE and retinal 
atrophy.31.32 Its bullseye like typical manifestations 
occur due to RPE depigmentation in a circle of the 
macular central fovea. European patients mostly 
present with typical parafoveal photoreceptor 
layer injury33, while Asian patients often present 
with injury near the vascular arch at the parafoveal 
margin.34 Some auxiliary examinations show 
abnormal results, such as multifocal 
electroretinography showing diminished 
perifoveal response and enhanced fundus 
autofluorescence, spectral-domain optical 
coherence tomography showing parafoveal 
thinning and destruction of the hierarchy of the 
external membrane and ellipsoid band, while the 
structure just below the fovea being relatively 
intact, presenting a flying saucer sign.35 Visual 
field detection results are characterized by 
bilateral reproducible persistent paracentral or 
central visual field blind spots under stimulation 
on the white light threshold and may also have 
other visual field abnormalities.36 If retinopathy 
occurs relatively slowly after medication, 
retinopathy should be closely monitored. If it is 
not enough to affect vision, it is unnecessary to 
discontinue the drug. Once retinal toxicity is 
significantly aggravated, the risk of continuing 
medication should be discussed with an 
ophthalmologist. In addition, the use of CQ and 
HCQ may cause vortex keratopathy or whorl 
keratopathy, but it is mostly reversible after 
discontinuation of the drug and there is no direct 
evidence related to the severity of retinopathy.37,38 
 
Retinal damage caused by HCQ and CQ is often 
irreversible, and screening, although not reducing 
drug-induced retinal damage, can detect retinal 
toxicity before vision is significantly affected, so as 
to guide medication. HCQ and CQ are potentially 
effective drugs for the treatment of COVID-19, and 
screening should be regarded as a means of 
preventing severe retinal damage to support the 
safe application of HCQ or CQ in patients and 
detect the potential risk of retinal damage at an 
early stage. If a patient has retinopathy, such as 
maculopathy, glaucoma, and so on, the drug 
should be used with caution, or the lower dose 
should be maintained. If there are signs of retinal 
damage during treatment, ophthalmic 
examinations should be repeated to verify the 
examination results. If it is determined that the 
damage occurs, the dose should be adjusted 
according to the patient’s actual conditions to 
control the progression of damage. For screening 
retinopathy due to early HCQ and CQ, visual field 
testing has good sensitivity, but reliability cannot 
be guaranteed due to the presence of subjective 
factors in patients. Some objective tests show a 
good sensitivity for early lesions, such as mfERG, 
SD-OCT and FAF. Therefore, it is recommended 
to combine with objective examination at the 
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same time of visual field testing to produce 
reliable screening results. 
 
Under the condition of excluding patient’s 
subjective factors, perimetry is a more sensitive 
method to detect the retinal condition of patients. 
For the screening of retinopathy caused by HCQ 
and CQ, foreign studies mostly recommend the 
use of the standard procedure of 10-2 visual fields 
with a white target, and it is believed that the test 
results have a good sensitivity.21 At the same time, 
the subjectivity of perimetry cannot be neglected, 
and the results of perimetry are not enough to be 
used as a confirmation of retinal damage, and 
repeated testing should be performed in 
combination with other objective test results. 
With the development of injuries caused by CQ 
and HCQ, SD-OCT examination can find damage 
to the parafoveal photoreceptor cell layer in 
European patients, while damage near the 
extrafoveal vascular arch is more common in 
Asian patients. Due to the different location of 
retinopathy in Asian patients compared to 
European patients, it is particularly important to 
perform wide-angle scanning or direct scanning of 
the vascular arch region in Asian patients. SD-
OCT examination in patients with advanced 
retinopathy caused by HCQ may present with a 
typical flying saucer sign, that is, a relatively 
normal foveal retina, thinning of the outer retina 
of the parafovea, destruction of structures such as 
the external membrane and ellipsoid zone, 
resembling a flying saucer shape.35 
 
SD-OCT may not be as sensitive as visual field 
testing and mfERG, but when local retinal 
thinning occurs, it is basically certain that retinal 
damage has been caused. mfERG can objectively 
record early lesions in the para-retinal fovea and 
extramacular regions by electrophysiological 
means, with a sensitivity close to that of 
perimetry, which can provide objective evidence 
for patients with abnormal perimetry.39 Studies 
have found that mfERG signal may be weakened 
after HCQ administration40, and mfERG signal 
may be recovered to some extent after drug 
discontinuation and has a negative correlation 
with drug accumulation41, suggesting that mfERG 
can be used as a reference index for drug dose 
adjustment. However, due to the low application 
rate of   mfERG,   there are limited physicians  who  
 
can skillfully complete the examination procedure, 
which limits the application of this method to 
some extent. FAF is of high value for the 
examination of posterior fundus injury and is most 
sensitive for the examination of RPE damage, 
which may detect early injury in macular foveal or 
extramacular photoreceptor before SD-OCT shows 
retinal thinning.42 When the damage reaches a 
late stage, RPE loss is manifested as a dark area 
with reduced autofluorescence. Wide-angle image 
mode should be used for Chinese patients when 
CQ and HCQ retinal toxicity is confirmed by FAF 
testing. When ophthalmoscopy can detect visible 
changes in the fundus, retinopathy often has 
reached an advanced stage of irreversible damage, 
and retinopathy can be detected earlier by other 
techniques.43  
 
At the same time, ophthalmoscopy performed at a 
close doctor-patient distance will increase the risk 
of exposure of ophthalmologists, so 
ophthalmoscopy is not recommended. Tests such 
as time-domain optical coherence tomography, 
fundus fluorescein angiography, full-field 
electroretinography, Amsler chart, color vision 
test, and electrooculography are not 
recommended screening methods due to 
insufficient sensitivity.23,44 It is worth mentioning 
that although full-field electroretinography cannot 
detect early retinopathy, it may be helpful in 
judging damage other than the macula.45 
 
There is no specific treatment for retinopathy 
caused by CQ and HCQ, so early preventive 
screening appears to be more important. Early 
macular changes may be reversible after 
discontinuation of the drug and damages caused 
at the advanced stage are irreversible. For most 
patients, retinopathy may tend to be stable after 
drug discontinuation, but some patients still have 
the possibility of progression of lesions after drug 
discontinuation, which may be related to slower 
metabolism of HQ.27 Once the occurrence of 
retinopathy is confirmed, clinicians should 
consider prompt discontinuation of medication 
and inform patients of the risk of further visual 
impairment based on the severity of retinopathy. 
It is generally recommended that patients with 
retinopathy caused by CQ and HCQ avoid 
excessive exposure to sunlight and ingest 
sufficient   lutein    and    zeaxanthin    to     protect  
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photoreceptor cells in the fovea; however, the 
practical value of these recommendations is 
unclear due to the lack of clinical evidence.21  
 
CONCLUSION 
Chloroquine and hydroxychloroquine have 
definite inhibitory effects on SARS-CoV-2, and 
they are recommended for the treatment of 
COVID-19. Retinal damage caused by it occurs 
mostly after long-term medication; however, due 
to different physical constitutions in different 
patients, there are also some differences in 
tolerance to the drug, short-term application of 
high-dose drugs can significantly increase the risk 
of retinal damage. Therefore, in the treatment of 
COVID-19 with CQ and HCQ, it is important to 
recognize the characteristics of retinopathy caused 
by such drugs, pay attention to adjusting the dose 
according to the actual conditions of patients, use 
necessary ophthalmic screening for patients at 
higher risk, and use relative caution in patients 
with retinal or macular diseases. The application 
of risk screening methods can help detect early 
retinal damage and guide clinical adjustment of 
medication dose. For patients with retinopathy, if 
necessary, the drug should be discontinued and 
switched to other therapeutic drugs. At present, 
CQ and HCQ have achieved promising 
therapeutic effects in the treatment of COVID-19. 
The proportion and severity of toxic retinopathy 
during the treatment remain to be further studied. 
Before the exact research results are obtained, we 
still need to exercise caution during the 
application of CQ and HCQ. 
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